Date: 2015-04-21
Type of information: Initiation of the trial
phase:
Announcement: initiation of the trial
Company: VolitionRx (Singapore) Hvidovre Hospital (Denmark)
Product: NuQ® assays
Action
mechanism: The NuQ® tests utilize the Company\'s proprietary Nucleosomics® technology platform, which identifies and measures circulating nucleosome structures for the presence of epigenetic cancer and signals within the blood. Clinical trials assessing the effectiveness of VolitionRx\'s assays include: Colorectal cancer: A 4,800 patient retrospective symptomatic population study (Hvidovre Hospital, University of Copenhagen, Denmark) A 14,000 patient prospective screening study (Hvidovre Hospital, University of Copenhagen, Denmark) A 250 patient prospective study (CHU-UCL Mont Godinne Hospital, Belgium) Lung cancer: A 600 patient prospective confirmatory study (University Hospital, Bonn, Germany) Prostate cancer: A retrospective study to establish the efficacy of VolitionRx\'s NuQ® tests to distinguish anaplastic prostate cancer, a particularly aggressive form of the disease, from typical castration resistant prostate cancer (CRPC), the less aggressive form (MD Anderson, Texas) A 120-patient prospective feasibility study (ImmuneHealth, Belgium) Ovarian cancer: A 40-patient prospective feasibility study (Singapore General Hospital, Singapore) 20 most prevalent cancers: A 4,000 patient prospective study that involves patients with the 20 most prevalent cancers at University Hospital in Bonn, Germany Endometriosis: a prospective study to assess VolitionRx\'s NuQ® tests for the diagnosis of endometriosis (the University of Oxford, United Kingdom)
Disease: precancerous colorectal polyps
Therapeutic area: Diagnostic - Cancer - Oncology
Country: Denmark
Trial details:
Latest
news: * On April 21, 2015, VolitionRx, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, announced that Hvidovre Hospital, University of Copenhagen, Denmark has initiated a study specifically to identify a NuQ® biomarker panel for the identification of patients with precancerous colorectal polyps, particularly those that are at high risk of becoming cancers. In the study, a set of approximately 800 blinded prospectively-collected blood samples will be analyzed, including: 300 patients with single or multiple precancerous polyp(s) (including approximately 100 patients whose polyps subsequently recurred after removal); 400 subjects with no polyps or colorectal cancers (both with and without other diseases); plus 100 early stage (I/II) colorectal cancer patients. The cohort will comprise high and low risk polyps of various histologies. Following collection, the samples will be analyzed by VolitionRx using up to 30 NuQ® assays.
